All In Biotech

Free tool

FAERS Monitor: Relexxii

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216117 or its brand name (Relexxii, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

6,997

Serious

4,351

62% of reports

Hospitalization

1,710

Death reported

442

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,049
  • headache399
  • fatigue357
  • anxiety352
  • off label use340
  • nausea333
  • toxicity to various agents333
  • product substitution issue290
  • drug abuse285
  • somnolence271
  • insomnia265
  • disturbance in attention240
  • decreased appetite231
  • suicidal ideation226
  • agitation219

Reports by year received

View as table
YearReports
20042
20051
20061
20073
20088
200918
201014
201118
201269
2013117
2014121
2015440
2016343
2017495
2018576
2019459
2020352
2021411
2022611
2023790
2024744
2025728
2026676

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,162 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product substitution issueSignal29015.213.63,828
disturbance in attentionSignal24013.411.92,744
drug abuseSignal28510.39.22,392
agitationSignal2199.07.91,548
suicidal ideationSignal2267.46.51,255
toxicity to various agentsSignal3335.95.41,373
somnolenceSignal2714.03.6625
anxietySignal3523.73.4706
insomniaSignal2653.02.7354
decreased appetiteSignal2313.02.6307
drug ineffectiveSignal1,0492.42.3906
headache3991.91.7178
fatigue3571.41.238
nausea3331.31.119
off label use3401.21.18

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.